Abstract
Objective: To investigate the clinical effect and safety of oxycodone hydrochloride sustained-release tablets in the treatment of advanced malignant tumor pain. Methods: From January 2016 to November 2016, 128 patients with advanced malignancy, 42 patients with gastric cancer, 18 patients with hepatocellular carcinoma, 35 patients with esophageal cancer and 33 patients with breast cancer were selected. All patients were randomly divided into study group and control group, 64 cases in each group, the study group of 42 male patients, 22 females, aged 32-68 years, mean 52.1 ± 1.8 years; control group of 38 male patients, female the patients in the study group received endoscopic therapy and antibiotics to prevent infection. The control group received only endoscopic therapy. Results: The pain relief rate of the study group was significantly lower than that of the control group and
the quality of life was higher than that of the control group. The incidence of adverse reactions was less in the study group than in the control group (P<0.05). Conclusion: The oxycodone hydrochloride sustained-release tablets has a significant clinical effect and a small side-effect in the treatment of advanced malignant tumor pain. It is of high clinical value.